{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:34:46Z","timestamp":1791408886426,"version":"4.3.3"},"reference-count":25,"publisher":"American Society of Hematology","issue":"1","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,14]]},"DOI":"10.1182\/bloodadvances.2024014255","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T15:23:41Z","timestamp":1728487421000},"page":"202-206","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1208-9260","authenticated-orcid":false,"given":"Zachary M.","family":"Avigan","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saoirse","family":"Bodnar","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Pan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerrel","family":"Catlett","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larysa J.","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana C.","family":"Rossi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-5757","authenticated-orcid":false,"given":"Hearn Jay","family":"Cho","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8454-5136","authenticated-orcid":false,"given":"Santiago","family":"Thibaud","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"issue":"11","key":"2025011416261557700_bib1","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2025011416261557700_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2025011416261557700_bib3","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/cancers14061501","article-title":"Cytopenia after CAR-T cell therapy-a brief review of a complex problem","volume":"14","author":"Sharma","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"15","key":"2025011416261557700_bib4","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2025011416261557700_bib5","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2025011416261557700_bib6","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2025011416261557700_bib7","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","article-title":"Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality","volume":"8","author":"Rejeski","year":"2024","journal-title":"Blood Adv"},{"issue":"38","key":"2025011416261557700_bib8","doi-asserted-by":"crossref","first-page":"eadg3919","DOI":"10.1126\/sciadv.adg3919","article-title":"Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion","volume":"9","author":"Rejeski","year":"2023","journal-title":"Sci Adv"},{"issue":"5","key":"2025011416261557700_bib9","doi-asserted-by":"crossref","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"7","key":"2025011416261557700_bib10","doi-asserted-by":"crossref","first-page":"E249","DOI":"10.1002\/ajh.26551","article-title":"Diminished durability of chimeric antigen receptor T-cell efficacy with severe or prolonged postinfusion cytopenias","volume":"97","author":"Tabbara","year":"2022","journal-title":"Am J Hematol"},{"issue":"6","key":"2025011416261557700_bib11","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1182\/bloodadvances.2023011727","article-title":"Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study)","volume":"8","author":"Vic","year":"2024","journal-title":"Blood Adv"},{"issue":"24","key":"2025011416261557700_bib12","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2025011416261557700_bib13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J\u00a0Hematol Oncol"},{"issue":"suppl 1","key":"2025011416261557700_bib14","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood-2023-190772","article-title":"Inflammatory marker levels, age, race and prior treatment burden independently predict delayed hematologic recovery after BCMA-directed CART therapy in multiple myeloma","volume":"142","author":"Thibaud","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2025011416261557700_bib15","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2025011416261557700_bib16","doi-asserted-by":"crossref","first-page":"e006406","DOI":"10.1136\/jitc-2022-006406","article-title":"Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party","volume":"11","author":"Penack","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"issue":"10","key":"2025011416261557700_bib17","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1200\/JCO.2009.24.3881","article-title":"Neutrophil count in African Americans: lowering the target cutoff to\u00a0initiate or resume chemotherapy?","volume":"28","author":"Hsieh","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2025011416261557700_bib18","first-page":"235","article-title":"Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials","volume":"142","author":"Kanapuru","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2025011416261557700_bib19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/bloodadvances.2022007679","article-title":"Absolute neutrophil count by Duffy status among healthy Black and African American adults","volume":"7","author":"Merz","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2025011416261557700_bib20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/ncomms1265","article-title":"The global distribution of the Duffy blood group","volume":"2","author":"Howes","year":"2011","journal-title":"Nat Commun"},{"issue":"20","key":"2025011416261557700_bib21","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1093\/hmg\/ddaa208","article-title":"The Duffy-null genotype\u00a0and risk of infection","volume":"29","author":"Legge","year":"2020","journal-title":"Hum Mol Genet"},{"issue":"suppl 1","key":"2025011416261557700_bib22","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1182\/blood-2023-187811","article-title":"When a number is just a number: Duffy-null blood group phenotype, absolute neutrophil count, and incidence of neutropenic fever and chemotherapy dose reductions in patients treated for plasma cell dyscrasias","volume":"142","author":"Abdallah","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2025011416261557700_bib23","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjh.15730","article-title":"The Duffy antigen receptor for chemokines, ACKR1,- 'Jeanne DARC' of benign neutropenia","volume":"184","author":"Rappoport","year":"2019","journal-title":"Br J Haematol"},{"issue":"7","key":"2025011416261557700_bib24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/ni.3763","article-title":"Atypical chemokine receptor 1 on nucleated erythroid cells regulates hematopoiesis","volume":"18","author":"Duchene","year":"2017","journal-title":"Nat Immunol"},{"issue":"23","key":"2025011416261557700_bib25","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1001\/jama.2023.7467","article-title":"Development of Duffy null-specific absolute neutrophil count reference ranges","volume":"329","author":"Merz","year":"2023","journal-title":"JAMA"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/1\/202\/2350361\/blooda_adv-2024-014255-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/1\/202\/2350361\/blooda_adv-2024-014255-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T11:26:39Z","timestamp":1736853999000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/1\/202\/518144\/Delayed-neutrophil-recovery-following-BCMA-CAR-T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014255","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]}}}